ALRN-0192519 / AstraZeneca, Allorion Therap - LARVOL DELTA

ALRN-0192519 is a potent and selective EGFR L858R mutation inhibitor that demonstrates anti-cancer activity in preclinical cancer models as monotherapy or in combination with osimertinib (AACR 2025) - "When combined with osimertinib, ALRN-0192519 delayed the tumor regrowth much longer than osimertinib alone, demonstrating the potential advantage of combination therapy. Taken together, these results support that ALRN-0192519 is a promising EGFR allosteric inhibitor for treating lung cancer patients with the EGFR L858R mutation as either monotherapy or in combination with osimertinib."

Combination therapy • Monotherapy • Preclinical • Lung Cancer • Oncology • Solid Tumor • EGFR

Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca (PRNewswire) - "Allorion Therapeutics...has entered into an exclusive option and global license agreement with AstraZeneca...to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC)....Under the terms of the agreement, AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally. Allorion is eligible to receive upfront and near-term payments of up to $40 million, and additional development and commercial milestone payments of over $500 million, as well as tiered royalties on net sales worldwide."

Licensing / partnership • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor